Aurinia Pharmaceuticals Inc. (AUPH) stock analysis

Healthcare · Biotechnology

From the 10-K filed 2026-02-26

How it makes money

Aurinia earns revenue by selling its oral therapy LUPKYNIS to a small group of specialty distributors and through an overseas partnership.

Aurinia generates its net product sales primarily through distribution channels in the United States, specifically two specialty pharmacies and a specialty distributor. It also sells inventory to its collaboration partner Otsuka Pharmaceutical Co., Ltd. for distribution in international markets like Europe and Japan.

Revenues are driven by the volume of cartons sold, which depends on expanding market penetration among patients suffering from lupus nephritis. The company also earns license, collaboration, and royalty revenue from Otsuka, including milestone payments and sales-based royalties ranging from 10% to 20% in designated territories.

What protects it: the moat

Management claims regulatory approval of its oral treatment and patent protection defend its market position against alternative therapies and off-label combinations.

The company relies on its status as the first FDA-approved oral therapy for adult patients with active lupus nephritis to secure its position in the market. Its intellectual property and specialized commercial organization are intended to maintain a competitive advantage.

However, management notes that LUPKYNIS faces competition from existing treatments such as BENLYSTA and GAZYVA, as well as physicians continuing to use off-label combinations of MMF and corticosteroids or first-generation calcineurin inhibitors.

What growth costs

Aurinia reinvests through research and development expenses, selling and marketing costs, restructuring outlays, and a fixed quarterly facility fee paid to a manufacturer.

To maintain and expand its operations, the company incurs ongoing selling, general, and administrative expenses to support its U.S. commercial organization and market presence. Research and development investments are directed toward developing new treatments like aritinercept for autoimmune diseases.

Additionally, the company pays a quarterly fixed facility fee of 3.6 million Swiss Francs through March 31, 2030, for the exclusive right to use a dedicated manufacturing facility built by its contract manufacturing partner, Lonza Ltd.

What could damage it

Inability to maintain an effective sales organization or shift physician treatment practices could severely limit product sales and harm financial results.

Because the business is substantially dependent on the commercial success of its sole approved product, any failure by its commercial team to promote the drug effectively would restrict growth. If physicians continue relying on established off-label treatments rather than adopting LUPKYNIS, net product sales would suffer.

Furthermore, changes in pricing strategies, reimbursement coverage, or the loss of key distribution partners could permanently impair the company's earnings capacity.

About Aurinia Pharmaceuticals Inc.

Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.

Other companies in Biotechnology